Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United Kingdom
/
Pharmaceuticals & Biotech
/
Shield Therapeutics
STX
Shield Therapeutics
Single Asset Dependency And US Pricing Challenges Will Mar Prospects
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
18 Aug 25
Updated
18 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
UK£0.032
120.3% overvalued
intrinsic discount
18 Aug
UK£0.07
Loading
1Y
90.5%
7D
53.3%
Author's Valuation
UK£0.03
120.3% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
UK£0.03
120.3% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-41m
108m
2014
2017
2020
2023
2025
2026
2028
Revenue US$107.8m
Earnings US$47.1m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
28.98%
Pharma revenue growth rate
0.57%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.82%
Calculation
US$47.07m
Earnings '28
x
1.17x
PE Ratio '28
=
US$54.97m
Market Cap '28
US$54.97m
Market Cap '28
/
1.04b
No. shares '28
=
US$0.05
Share Price '28
US$0.05
Share Price '28
Discounted to 2025 @ 6.82% p.a.
=
US$0.043
Fair Value '25
US$0.043
Fair Value '25
Converted to GBP @ 0.7387 USD/GBP Exchange Rate
=
UK£0.032
Fair Value '25
